16:05 EST Arcutis gets $25M upfront in partnership deal with Japan's Sato for roflumilast

Arcutis Biotherapeutics and Sato Pharmaceutical announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Japan. Sato will receive an exclusive license for both the cream and foam formulations of topical roflumilast, a next generation phosphodiesterase type 4 or PDE4, inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, atopic dermatitis, and potentially additional dermatological conditions in the future...